X

News

Jesse’s Journey grants $1M toward the launch of a clinical trial for Duchenne muscular dystrophy in Canada

Rockville MD, 11 June 2020

Jesse’s Journey, Canada’s leader in Duchenne muscular dystrophy funded research, is proud to announce a $1M grant towards a clinical trial evaluating vamorolone for the first time in More >

More >

ReveraGen BioPharma completes 2.5 years vamorolone treatment of 41 Duchenne muscular dystrophy boys

Rockville MD, 2 June 2020

Vamorolone is a first-in-class daily oral drug being developed to improve muscle function in Duchenne muscular dystrophy. Vamorolone has multiple mechanisms of action shown by published pre-clinical studies, including potent anti-inflammatory  More >

More >

ReveraGen BioPharma receives National Institutes of Health ethics grant to return data to participants in vamorolone clinical trials

Rockville MD, 22 October 2019

The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (USA) has awarded an ethics research grant to ReveraGen BioPharma to return patient-level and aggregate data to More>

More >

Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRA

Rockville, MD, 21 October 2019

Santhera Pharmaceuticals announces that the UK’s Medicines and Healthcare Products Regulatory Agency has informed ReveraGen BioPharma about having designated vamorolone a Promising Innovative Medicine . . .

More >

More >

Vamorolone Designated Promising Innovative Medicine (PIM) for treatment in Duchenne muscular dystrophy

Rockville, MD, 17 October 2019

In the UK the Early Access to Medicines Scheme (EAMS) is a regulatory path by the MRHA that aims to give patients with life threatening or . . . More >

More >

Top-line data of 18-month vamorolone treatment of Duchenne muscular dystrophy patients shows continued improvement of symptoms with reduction in corticosteroid safety concerns

Rockville, MD –  5 October 2019
A presentation at the 24th International Annual Congress of the World Muscle Society (WMS) in Copenhagen, Denmark reported top-line data from 18-month treatment of Duchenne muscular dystrophy (DMD) patients (VBP15-LTE trial).  More >

More >

Vamorolone Treatment of Duchenne Muscular Dystrophy Patients Leads to Improvements in Motor Function

Rockville, MD –  18 August 2019
A publication in the journal Neurology was released today describing efficacy studies of vamorolone, a treatment option being evaluated as a potentially safer alternative to corticosteroids, in boys with Duchenne muscular dystrophy. More

More >

Vamorolone (VBP15) First-in-patient Studies in Duchenne Muscular Dystrophy Published

Rockville, MD –  2 October 2018
A clinical trial of vamorolone in 48 boys with Duchenne muscular dystrophy entitled “Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug” has been More >

More >

ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy

Rockville, MD –  22 August 2018
ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy. More >

More >

Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy

Rockville, MD – 26 June 2018
Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy.

More >

More >